- Targeted stakeholdersExpanded research funding could accelerate development of improved PMDD diagnostics and treatments.
- Targeted stakeholdersProvider education may increase accurate diagnoses and reduce misdiagnosis of PMDD.
- Targeted stakeholdersPublic awareness campaigns may reduce stigma and increase timely care-seeking.
Premenstrual Dysphoric Disorder Awareness and Research Act of 2026
Referred to the House Committee on Energy and Commerce.
This bill directs HHS/NIH to expand and intensify research on Premenstrual Dysphoric Disorder (PMDD), collect surveillance data, run a public awareness campaign, develop provider education, award training grants, and report to Congress.
It authorizes “such sums as necessary” for fiscal years 2026–2031 for these activities.
Content is administratively centered and nonpolarizing, improving chances; actual enactment depends on appropriations and Senate floor dynamics.
Relative to its intended legislative type, this bill is a substantive policy measure that establishes new programmatic directives for federal health agencies to expand research, surveillance, public education, provider training, and reporting on PMDD. It clearly defines the problem and assigns responsibilities, but leaves many operational, fiscal, and evaluative specifics to agency implementation or future appropriations.
Funding vagueness: liberals want explicit dollars; conservatives want caps
Who stands to gain, and who may push back.
- Federal agenciesThe bill authorizes open-ended federal spending without specified appropriations amounts.
- Targeted stakeholdersImplementing programs will impose administrative and reporting burdens on HHS, NIH, and HRSA.
- Targeted stakeholdersUnspecified appropriations risk diverting discretionary funds from other public health priorities.
Why the argument around this bill splits.
Funding vagueness: liberals want explicit dollars; conservatives want caps
Overall supportive: views the bill as addressing an under-researched, stigmatized health condition affecting reproductive-age people.
Sees value in research, provider training, public education, and improved data, but may want stronger commitments on funding, access, and inclusion.
Generally favorable but pragmatic: supports research and education for a real medical need while wanting cost controls, outcome measures, and coordination to avoid duplication.
Prefers measurable goals and oversight.
Skeptical but not uniformly opposed: may accept targeted research and education, yet worries about federal program expansion, open-ended spending, and bureaucratic growth.
Would press for spending limits and state/family authority protections.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is administratively centered and nonpolarizing, improving chances; actual enactment depends on appropriations and Senate floor dynamics.
- No cost estimate or fiscal magnitude provided
- Actual funding depends on future appropriations decisions
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Funding vagueness: liberals want explicit dollars; conservatives want caps
Content is administratively centered and nonpolarizing, improving chances; actual enactment depends on appropriations and Senate floor dyna…
Relative to its intended legislative type, this bill is a substantive policy measure that establishes new programmatic directives for federal health agencies to expand research, surveillance, public education, provider…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.